Genomics

Dataset Information

0

CDK4/6 inhibitors in ER positive breast cancers

ABSTRACT: Gene expression levels were determined with control or PD-0332991 treatment

ORGANISM(S): Homo sapiens

PROVIDER: GSE80987 | GEO | 2016/08/01

SECONDARY ACCESSION(S): PRJNA320258

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics CDK4/6 inhibitors in ER positive breast cancers
2016-08-01 | E-GEOD-80987 | biostudies-arrayexpress
Transcriptomics Metabolic re-programming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities
2015-12-21 | E-GEOD-75979 | biostudies-arrayexpress
Transcriptomics Metabolic re-programming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities
2015-12-21 | GSE75979 | GEO
Unknown Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
| S-EPMC4794996 | biostudies-literature
Transcriptomics Gene expression profiling of HepG2 cells after treatment of PD-0332991 and CDK4-6 Knockdown
2020-02-18 | GSE145389 | GEO
Unknown Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
| S-EPMC6472385 | biostudies-literature
Unknown Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
| S-EPMC7744368 | biostudies-literature
Unknown ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.
| S-EPMC6690756 | biostudies-literature
Transcriptomics Cdk4 is a critical regulator of age-associated hepatic steatosis.
2018-04-01 | GSE104395 | GEO
Unknown Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
| S-EPMC6435685 | biostudies-literature